Trials of a human blood-based Covid-19 treatment that was granted emergency authorization by the U.S. will be expanded to prove whether it’s safe and effective.
Two human studies of convalescent plasma, a component of blood taken from recovered coronavirus patients, will enroll more patient at hospitals and clinics across the country, with $48 million from the Operation Warp Speed program to accelerate drug and vaccine development.
“The evidence on convalescent plasma as a treatment for severe cases of Covid-19 is promising but incomplete,” National Institutes of Health Director Francis Collins said Tuesday in a statement. “We need to carry out rigorous randomized control clinical trials to determine how this therapy can improve outcomes.”
President Donald Trump and Food and Drug Administration Commissioner Stephen Hahn last month announced an emergency-useauthorization for convalescent plasma, which is thought to contain factors that control disease, calling it a “milestone achievement.” Hahn misstated the therapy’s impact on patient deaths in a press conference, leading observers like philanthropist Bill Gates to question the agency’scredibility in the pandemic.
75,083 in IndiaMost new cases today
-3% Change in MSCI World Index of global stocks since Wuhan lockdown, Jan. 23
-1.068 Change in U.S. treasury bond yield since Wuhan lockdown, Jan. 23
5.3% Global GDP Tracker (annualized), Aug.